Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron (NASDAQ: LGVN) reported Q1 2026 revenue of $0.4 million, flat year over year, and a net loss of $4.7 million versus $5.0 million in Q1 2025. Cash and equivalents were $15.8 million, with runway into Q4 2026.
The company closed a private placement of up to $30 million, including $15 million initially funded, and targets August 2026 top-line Phase 2b ELPIS II results in hypoplastic left heart syndrome while pursuing partnerships across its HLHS, Alzheimer’s, pediatric dilated cardiomyopathy and aging-related frailty programs.
Longeveron (NASDAQ: LGVN) reported that an independent Data Monitoring Committee completed its final planned review of the fully enrolled Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) for hypoplastic left heart syndrome (HLHS).
The DMC found no new safety concerns, recommended the study continue as designed, and top-line results are anticipated in August 2026. ELPIS II enrolled 40 pediatric patients at 12 centers and is conducted with NHLBI support. Prior ELPIS I data showed 100% transplant-free survival to age five in treated children. Laromestrocel holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS.
Longeveron (NASDAQ: LGVN) held a Type C meeting with the U.S. FDA; the Agency said right ventricle ejection fraction (RVEF) is not an appropriate primary endpoint for the ELPIS II Phase 2b trial for hypoplastic left heart syndrome. Top-line results are anticipated in August 2026. The FDA will not agree a new primary endpoint while the trial remains ongoing because of an interim NIH-mandated analysis, and therefore no longer describes ELPIS II as pivotal. The FDA said objective measures (all-cause mortality, transplant-free survival, cardiac transplantation, well-defined MACE) could be informative. Longeveron will submit a Sponsor Statistical Analysis Plan proposing a composite primary endpoint and remains optimistic about a possible BLA path after readout.
Longeveron (NASDAQ: LGVN) will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference call number: 1.877.407.0789 with Conference ID 13759888. A replay will be available in the Events & Presentations section of the company website following the call.
Longeveron (NASDAQ: LGVN) announced that China Patent No. 2026031300230720, entitled “Potency Assay,” was granted by the China National Intellectual Property Administration and provides patent protection in China through 2041 assuming annuity fees are paid.
This patent covers potency assay methods for assessing human mesenchymal stem cells (MSCs) from multiple tissue sources and expands Longeveron’s international portfolio to 52 patents. The company is also advancing a Phase 2b HLHS trial with results expected in Q3 2026, which could support a U.S. BLA depending on outcomes.
Longeveron (NASDAQ: LGVN) reported 2025 results and a business update on March 17, 2026. Revenues fell 50% to $1.2M; net loss widened to $22.7M. The company closed an initial $15M private placement (up to $30M) and expects pivotal Phase 2b ELPIS II HLHS topline results in Q3 2026.
Management plans partnering strategies, expects a potential BLA path for HLHS if ELPIS II is successful, and projects cash runway into Q4 2026 after the transaction.
Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. An archived replay will be available on the company website under Events & Presentations.
Longeveron (NASDAQ: LGVN) closed an initial tranche of a private placement on March 11, 2026, raising approximately $15 million upfront, with eligibility for an additional ~$15 million tied to milestone conditions from its Phase 2b ELPIS II HLHS trial. The financing was priced at-the-market under Nasdaq rules and led by Coastlands Capital with participation from Janus Henderson and other healthcare funds. The company issued 6,013,384 Class A shares at $0.52 and Series A non-voting convertible preferred shares convertible into 22,832,770 Class A shares at $0.52. Net proceeds are expected to extend the cash runway into 4Q26, past the anticipated 3Q26 topline readout, and the company sold investors rights to 50% of net proceeds from any future Rare Pediatric Disease Priority Review Voucher receipt for its laromestrocel HLHS program.
Longeveron (NASDAQ: LGVN) entered a private placement expected to raise up to $30 million in gross proceeds, with an initial closing of approximately $15 million priced at-the-market under Nasdaq rules.
Initial proceeds fund operations into 4Q2026, past anticipated pivotal Phase 2b ELPIS II HLHS topline data in 3Q2026. The financing includes Class A shares and Series A non-voting convertible preferred shares convertible at $0.52, and a contingent second tranche tied to trial milestones and share price.
Longeveron (NASDAQ: LGVN) reported Phase 2b results published in Cell Stem Cell showing intravenous laromestrocel improved physical condition in 148 ambulatory patients with age-related frailty versus placebo. 6-minute walk test (6MWT) increased by 63.4m at month 9 (95% CI: 17.1–109.6m; p=0.0077). Findings include dose-response signals and a potential TIE-2 biomarker for responsiveness.